Skip to main content
SpringerLink
Log in

Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC

  • Original Paper
  • Published:
Cellular Oncology Aims and scope Submit manuscript

Abstract

Aim

To explore the association between the galectin-3 genetic polymorphisms and Platinum-based chemotherapy response as well as the prognosis of non-small cell lung cancer (NSCLC).

Method

Three hundred twenty patients with Stage III (A+B) or IV NSCLC were enrolled. A Platinum-based chemotherapy was given to each subjects and therapeutic effect was evaluated. The two galectin-3 genetic polymorphisms, namely, galectin-3 +191 A>C and +292 A>C, were genotyped.

Results

The polymorphic genotypes and the allele frequency of galectin-3 +191 A>C were not significantly different between responders and non-responders to chemotherapy. For galectin-3 +292 A>C, the AA genotype and A allele distribution were significantly higher in responders than in non-responders. Logistic regression analysis showed CC genotype of galectin-3 +292 presented higher risk of being non-responders compared with the AA genotype (OR = 2.96, 95 % CI: 1.55–5.47; P < 0.001). The overall survival in patients with AA genotype of galectin-3 +292 were significantly longer than in those with CC genotype (25.6 vs. 19.5 months, P = 0.013). The hazard ratio for CC genotype of galectin-3 +292 was 2.43 (95 % CI: 2.03–3.98, compared with AA carriers, P = 0.003).

Conclusion

The galectin-3 genetic polymorphisms of galectin-3 +292, rather than galectin-3 +191, were associated with the chemotherapy response and prognosis of NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Z. Liao, S.H. Lin, J.D. Cox, Status of particle therapy for lung cancer. Acta Oncol. 50(6), 745–756 (2011)

    Article  PubMed  Google Scholar 

  2. H. Watanabe, S. Yamamoto, H. Kunitoh, I. Sekine, N. Yamamoto, Y. Ohe, T. Tamura, T. Kodama, K. Sugimura, N. Saijo, Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci. 94(11), 1015–1020 (2003)

    Article  PubMed  CAS  Google Scholar 

  3. E. Nakajima, H. Katou, Adjuvant chemotherapy for resectable non-small cell lung cancer (NSCLC). Kyobu Geka 61(1), 4–8 (2008)

    PubMed  Google Scholar 

  4. R.P. Perng, C.H. Yang, Y.M. Chen, G.C. Chang, M.C. Lin, R.K. Hsieh, N.M. Chu, R.S. Lai, W.C. Su, C.J. Tsao et al., High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 62(1), 78–84 (2008)

    Article  PubMed  Google Scholar 

  5. A. Chang, Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71(1), 3–10 (2011)

    Article  PubMed  Google Scholar 

  6. O. Gautschi, B. Hugli, A. Ziegler, C. Bigosch, N.L. Bowers, D. Ratschiller, M. Jermann, R.A. Stahel, J. Heighway, D.C. Betticher, Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 51(3), 303–311 (2006)

    Article  PubMed  Google Scholar 

  7. C. Zhou, S. Ren, S. Zhou, L. Zhang, C. Su, Z. Zhang, Q. Deng, J. Zhang, Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn. J. Clin. Oncol. 40(10), 954–960 (2010)

    Article  PubMed  Google Scholar 

  8. L.H. Cui, Z. Yu, T.T. Zhang, M.H. Shin, H.N. Kim, J.S. Choi, Influence of polymorphisms in MTHFR 677 C-->T, TYMS 3R-->2R and MTR 2756 A-->G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC. Pharmacogenomics 12(6), 797–808 (2011)

    Article  PubMed  CAS  Google Scholar 

  9. K.C. Haudek, K.J. Spronk, P.G. Voss, R.J. Patterson, J.L. Wang, E.J. Arnoys, Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim. Biophys. Acta 1800(2), 181–189 (2010)

    Article  PubMed  CAS  Google Scholar 

  10. V. Balan, P. Nangia-Makker, Y.S. Jung, Y. Wang, A. Raz, Galectin-3: a novel substrate for c-Abl kinase. Biochim. Biophys. Acta 1803(10), 1198–1205 (2010)

    Article  PubMed  CAS  Google Scholar 

  11. S. Saussez, C. Decaestecker, V. Mahillon, S. Cludts, A. Capouillez, D. Chevalier, H.K. Vet, S. Andre, G. Toubeau, X. Leroy et al., Galectin-3 upregulation during tumor progression in head and neck cancer. Laryngoscope 118(9), 1583–1590 (2008)

    Article  PubMed  CAS  Google Scholar 

  12. C.G. Chiu, S.S. Strugnell, O.L. Griffith, S.J. Jones, A.M. Gown, B. Walker, I.R. Nabi, S.M. Wiseman, Diagnostic utility of galectin-3 in thyroid cancer. Am. J. Pathol. 176(5), 2067–2081 (2010)

    Article  PubMed  CAS  Google Scholar 

  13. Y. Wang, P. Nangia-Makker, L. Tait, V. Balan, V. Hogan, K.J. Pienta, A. Raz, Regulation of prostate cancer progression by galectin-3. Am. J. Pathol. 174(4), 1515–1523 (2009)

    Article  PubMed  CAS  Google Scholar 

  14. K. Tsuboi, T. Shimura, N. Masuda, M. Ide, S. Tsutsumi, S. Yamaguchi, T. Asao, H. Kuwano, Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res. 27(4B), 2289–2296 (2007)

    PubMed  CAS  Google Scholar 

  15. S.H. Park, H.S. Min, B. Kim, J. Myung, S.H. Paek, Galectin-3: a useful biomarker for differential diagnosis of brain tumors. Neuropathology 28(5), 497–506 (2008)

    Article  PubMed  Google Scholar 

  16. R. Shalom-Feuerstein, R. Levy, V. Makovski, A. Raz, Y. Kloog, Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras. Biochim. Biophys. Acta 1783(6), 985–993 (2008)

    Article  PubMed  CAS  Google Scholar 

  17. C.Y. Hu, S.K. Chang, C.S. Wu, W.I. Tsai, P.N. Hsu, Galectin-3 gene (LGALS3) +292C allele is a genetic predisposition factor for rheumatoid arthritis in Taiwan. Clin. Rheumatol. 30(9), 1227–1233 (2011)

    Article  PubMed  Google Scholar 

  18. P. Matarrese, O. Fusco, N. Tinari, C. Natoli, F.T. Liu, M.L. Semeraro, W. Malorni, S. Iacobelli, Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int. J. Cancer 85(4), 545–554 (2000)

    Article  PubMed  CAS  Google Scholar 

  19. R.A. Pacis, M.J. Pilat, K.J. Pienta, K. Wojno, A. Raz, V. Hogan, C.R. Cooper, Decreased galectin-3 expression in prostate cancer. Prostate 44(2), 118–123 (2000)

    Article  PubMed  CAS  Google Scholar 

  20. C.I. Lin, E.E. Whang, D.B. Donner, X. Jiang, B.D. Price, A.M. Carothers, T. Delaine, H. Leffler, U.J. Nilsson, V. Nose et al., Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol. Cancer Res. 7(10), 1655–1662 (2009)

    Article  PubMed  CAS  Google Scholar 

  21. M.M. Kadrofske, K.P. Openo, J.L. Wang, The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch. Biochem. Biophys. 349(1), 7–20 (1998)

    Article  PubMed  CAS  Google Scholar 

  22. E.A. Barboni, S. Bawumia, K. Henrick, R.C. Hughes, Molecular modeling and mutagenesis studies of the N-terminal domains of galectin-3: evidence for participation with the C-terminal carbohydrate recognition domain in oligosaccharide binding. Glycobiology 10(11), 1201–1208 (2000)

    Article  PubMed  CAS  Google Scholar 

  23. N. Ahmad, H.J. Gabius, S. Andre, H. Kaltner, S. Sabesan, R. Roy, B. Liu, F. Macaluso, C.F. Brewer, Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J. Biol. Chem. 279(12), 10841–10847 (2004)

    Article  PubMed  CAS  Google Scholar 

  24. N. Ahmad, H.J. Gabius, S. Sabesan, S. Oscarson, C.F. Brewer, Thermodynamic binding studies of bivalent oligosaccharides to galectin-1, galectin-3, and the carbohydrate recognition domain of galectin-3. Glycobiology 14(9), 817–825 (2004)

    Article  PubMed  CAS  Google Scholar 

  25. I. Pelletier, S. Sato, Specific recognition and cleavage of galectin-3 by Leishmania major through species-specific polygalactose epitope. J. Biol. Chem. 277(20), 17663–17670 (2002)

    Article  PubMed  CAS  Google Scholar 

  26. J.P. Gorski, F.T. Liu, A. Artigues, L.F. Castagna, P. Osdoby, New alternatively spliced form of galectin-3, a member of the beta-galactoside-binding animal lectin family, contains a predicted transmembrane-spanning domain and a leucine zipper motif. J. Biol. Chem. 277(21), 18840–18848 (2002)

    Article  PubMed  CAS  Google Scholar 

  27. V. Balan, P. Nangia-Makker, A.G. Schwartz, Y.S. Jung, L. Tait, V. Hogan, T. Raz, Y. Wang, Z.Q. Yang, G.S. Wu et al., Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res. 68(24), 10045–10050 (2008)

    Article  PubMed  CAS  Google Scholar 

  28. T. Yoshii, T. Fukumori, Y. Honjo, H. Inohara, H.R. Kim, A. Raz, Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J. Biol. Chem. 277(9), 6852–6857 (2002)

    Article  PubMed  Google Scholar 

  29. Y.J. Lee, Y.K. Song, J.J. Song, R.R. Siervo-Sassi, H.R. Kim, L. Li, D.R. Spitz, A. Lokshin, J.H. Kim, Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Exp. Cell Res. 288(1), 21–34 (2003)

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Dr. Xenia Ma for her help in statistic analyses and we thank Dr. Li Jiao for his help in writing this manuscript.

Author information

Authors and Affiliations

  1. Department of oncology, First People Hospital of Lianyungang, Lianyungang, Jiangsu province, 222002, China

    Fenglei Wu, Nan Hu, Yu Li, Baoxiang Bian, Guanghui Xu & Yitong Zheng

Authors
  1. Fenglei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Baoxiang Bian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guanghui Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yitong Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yitong Zheng.

Additional information

F. Wu and N. Hu contributed equally to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, F., Hu, N., Li, Y. et al. Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC. Cell Oncol. 35, 175–180 (2012). https://doi.org/10.1007/s13402-012-0075-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13402-012-0075-7

Keywords

Search

Navigation